Abstract:Cutaneous squamous carcinoma is the second most common epithelial malignancy, associated with significant morbidity, mortality, and economic burden. However, the mechanisms underlying cSCC remain poorly understood. In this study, we identified TGM3 as a novel cSCC tumor suppressor that acts via the PI3K-AKT axis. RT-qPCR, IHC and western blotting were employed to assess TGM3 levels. TGM3-overexpression/knockdown cSCC cell lines were utilized to detect TGM3's impact on epithelial differentiation as well as tumor cell proliferation, migration, and invasion in vitro. Additionally, subcutaneous xenograft tumor models were employed to examine the effect of TGM3 knockdown on tumor growth in vivo. Finally, molecular and biochemical approaches were employed to gain insight into the tumor-suppressing mechanisms of TGM3. TGM3 expression was increased in well-differentiated cSCC tumors, whereas it was decreased in poor-differentiated cSCC tumors. Loss of TGM3 is associated with poor differentiation and a high recurrence rate in patients with cSCC. TGM3 exhibited tumor-suppressing activity by regulating cell proliferation, migration, and invasion both in vitro and in vivo. As a novel cSCC tumor differentiation marker, TGM3 expression was positively correlated with cell differentiation. In addition, our results demonstrated an interaction between TGM3 and KRT14 that aids in the degradation of KRT14. TGM3 deficiency disrupts keratinocytes differentiation, and ultimately leads to tumorigenesis. Furthermore, RNA-sequence analysis revealed that loss of TGM3 enhanced EMT via the PI3K-AKT signaling pathway. Deguelin, a PI3K-AKT inhibitor, blocked cSCC tumor growth induced by TGM3 knockdown in vivo. Taken together, TGM3 inhibits cSCC tumor growth via PI3K-AKT signaling, which could also serve as a tumor differentiation marker and a potential therapeutic target for cSCC.

Reduced N-acetylglucosaminyltransferase III Expression Via Smad3 and Erk Signaling in TGF-β1-induced HCC EMT Model.

TGM3 Promotes Epithelial-Mesenchymal Transition and Hepatocellular Carcinogenesis and Predicts Poor Prognosis for Patients after Curative Resection.

GCNT3 Promotes Hepatocellular Carcinoma Progression and EMT by Activating the PI3K/AKT Pathway

GCNT3 regulated MUC13 to promote the development of hepatocellular carcinoma through the GSK3β/β-catenin pathway

Downregulation of the Gnt-V Gene Inhibits Metastasis and Invasion of Bgc823 Gastric Cancer Cells

Transglutaminase 3 Protein Modulates Human Esophageal Cancer Cell Growth by Targeting the NF-κB Signaling Pathway.

c-Jun-dependent β3GnT8 promotes tumorigenesis and metastasis of hepatocellular carcinoma by inducing CD147 glycosylation and altering N -glycan patterns.

STAT3 aggravates TGF-β1 induced epithelial-to-mesenchymal transition in hepatocellular carcinoma cells

Glypican-3 Promotes Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells Through Erk Signaling Pathway

The Role of N-acetylglucosaminyltransferases V in the Malignancy of Human Hepatocellular Carcinoma

TGF-β1 induced deficiency of linc00261 promotes epithelial–mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3

Neurotrophin3 promotes hepatocellular carcinoma apoptosis through the JNK and P38 MAPK pathways

EIF3B affects the invasion and metastasis of hepatocellular carcinoma cells via the TGFBI/MAPK/ERK pathway

Transglutaminase 3 regulates cutaneous squamous carcinoma differentiation and inhibits progression via PI3K-AKT signaling pathway-mediated Keratin 14 degradation

The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition

STAT3 Aggravates TGF-β1-induced Hepatic Epithelial-to-mesenchymal Transition and Migration.

TLX3 Repressed SNAI1-induced Epithelial-Mesenchymal Transition by Directly Constraining STAT3 Phosphorylation and Functionally Sensitized 5-FU Chemotherapy in Hepatocellular Carcinoma

CMTM3 Decreases EGFR Expression and EGF-mediated Tumorigenicity by Promoting Rab5 Activity in Gastric Cancer.

Decreased Expression of ATF3, Orchestrated by Β-Catenin/tcf3, Mir-17-5p and HOXA11-AS, Promoted Gastric Cancer Progression Via Increased Β-Catenin and CEMIP

The TTYH3/MK5 Positive Feedback Loop Regulates Tumor Progression Via GSK3-β/β-catenin Signaling in HCC

GP73, a novel TGF-β target gene, provides selective regulation on Smad and non-Smad signaling pathways